Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
NCT01547741
Unknown
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/13/2022
Locations: Texas Cancer Center, Abilene, Texas +34 locations
Conditions: Breast Cancer
Register for Updates
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NCT00887536
Completed
The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this stud... Read More
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
04/13/2022
Locations: Texas Cancer Center - Abilene South, Abilene, Texas +56 locations
Conditions: Breast Cancer
Register for Updates
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
NCT00567567
Completed
This randomized phase III trial compares two different high-dose chemotherapy regimens followed by a stem cell transplant in treating younger patients with high-risk neuroblastoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments before a... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/01/2022
Locations: Dell Children's Medical Center of Central Texas, Austin, Texas +6 locations
Conditions: Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Register for Updates
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
NCT01026220
Completed
This phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
04/01/2022
Locations: Dell Children's Medical Center of Central Texas, Austin, Texas +10 locations
Conditions: Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Register for Updates
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
NCT03836352
Active Not Recruiting
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2022
Locations: Mary Crowley Cancer Research Center, Dallas, Texas +1 locations
Conditions: Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer, Microsatellite Instability-High
Register for Updates
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
NCT02013336
Unknown
This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
Gender:
ALL
Ages:
Between 12 months and 20 years
Trial Updated:
03/17/2022
Locations: UT Southwestern, Dallas, Texas +2 locations
Conditions: Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma
Register for Updates
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
NCT00667329
Completed
The goal of this clinical research study is to see how well the drugs 2CdA, cyclophosphamide, and rituximab (rituxan) shrink a lymphoma called Waldenstrom's macroglobulinemia. After these drugs are given for 2 courses, a second goal is to see how long a remission lasts. A third goal is to see how often repeat remissions can be achieved when the lymphoma returns later and the same drugs are restarted. This is an investigational study. The FDA has approved each of these drugs for the treatment of... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2022
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
NCT02643420
Completed
The purpose of this study was to compare the efficacy of a single dose of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the duration of severe neutropenia (DSN) in Cycle 1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2022
Locations: CHI St. Joseph Health Cancer Center, Bryan, Texas +4 locations
Conditions: Neutropenia, Breast Cancer
Register for Updates
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
NCT02953340
Completed
The purpose of this study is to compare the efficacy of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) as measured by the duration of severe neutropenia (DSN).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2022
Locations: CHI St Joseph Health Cancer Center, Bryan, Texas +3 locations
Conditions: Neutropenia, Breast Cancer
Register for Updates
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
NCT02354547
Suspended
The purpose of this study is to determine the dose limiting toxicities and recommended phase 2 dose of SGT-53 alone and in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory solid tumors.
Gender:
ALL
Ages:
Between 12 months and 21 years
Trial Updated:
02/07/2022
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Neoplasm
Register for Updates
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
NCT00477412
Completed
This phase I/II trial studies the side effects and best dose of bortezomib when given with rituximab and chemotherapy drugs and to see how well they work in treating participants with mantle cell lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, de... Read More
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
01/27/2022
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Mantle Cell Lymphoma
Register for Updates
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
NCT00867178
Completed
This pilot clinical trial studies the side effects and the best way to give vorinostat with isotretinoin and combination chemotherapy and to see how well they work in treating younger patients with embryonal tumors of the central nervous system. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as isotretinoin, vincristine sulfate, cisplatin, cyclophosphamide, and etoposide phosphate, work in different ways to s... Read More
Gender:
ALL
Ages:
Between 2 months and 47 months
Trial Updated:
01/12/2022
Locations: M D Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Medulloblastoma, Pineoblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified
Register for Updates